Lescol
(fluvastatin)ApprovedSmall molecule
NovartisFluvastatin is used to lower cholesterol levels in the blood and reduce the risk of heart disease and stroke. It helps prevent fatty buildup in arteries that can block blood flow.[2] Lescol is currently approved and in use across 14 indications[4].[1]
Lescol is one of 293 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
14
Indications
31
Total Trials
0
Active Trials
292
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Lescol
NovartisApproved
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Mekinist
NovartisPhase 3
Cotellic
RochePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Lenvima
EisaiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metabolic Syndrome2 trials
Hepatitis C2 trials
Fluvastatin Versus Hepatitis C Virus
Completed·—·N/A·NCT00441493·32 enrolled
Acute Coronary Syndrome2 trials
Aortic Stenosis2 trials
Statin2 trials
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
Completed·—·Phase 2·NCT00487318·40 enrolled
20 more indications
Familial Hypercholesterolemia2 trials
Atherosclerosis1 trial
Fluvastatin AmelIorates aTHerosclerosis Study
Unknown status·—·Phase 4·NCT01681199·140 enrolled
Homozygous Familial Hypercholesterolemia1 trial
Antiphospholipid Syndrome1 trial
Hypercholesterolemia1 trial
High Cardiovascular Risk1 trial
Renal Transplant1 trial
Prostate Cancer1 trial
Platelet Aggregation1 trial
Metastasis1 trial
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
Withdrawn·—·Phase 1·NCT04285749
Diabetes1 trial
High Potency Statins and the Risk of Diabetes
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02518503·136,966 enrolled
Acute Kidney Injury1 trial
High Potency Statins and Acute Kidney Injury
Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02518516·2,067,639 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 31, 1993
LESCOL
NDA NDA020261
Oct 6, 2000
LESCOL XL
NDA NDA021192
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lescol drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for fluvastatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]